As a leading independent diagnostic laboratory, LabCorp participates in a highly attractive duopoly that offers favorable prospects as healthcare moves toward reformed payment models, Medicare headwinds are again delayed, and potentially positive M&A opportunities rise.
Now that commercial payers are moving away from exclusive contracts with the large independent labs, we think the prospect of cutthroat pricing competition has eased.
If significant numbers of hospital-based labs are ill-equipped to comply with Medicare's payment reporting requirements, then reimbursement pressure could increase even more in 2025-27.
|
Metric
|
LH
|
SHL
|
MYGN
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.79 | 23.87 | — |
Price/Book Value | 2.16 | 1.59 | 2.97 |
Price/Sales | 1.43 | 1.46 | 2.74 |
Price/Cash Flow | 11.56 | 10.72 | — |
|
Metric
|
LH
|
SHL
|
MYGN
|
|---|---|---|---|
Quick Ratio | 0.58 | 0.78 | 1.52 |
Current Ratio | 0.88 | 0.94 | 1.99 |
Interest Coverage | 4.03 | 5.95 | −81.03 |
|
Metric
|
LH
|
SHL
|
MYGN
|
|---|---|---|---|
Return on Assets (Normalized) | 6.77% | 4.07% | −0.45% |
Return on Equity (Normalized) | 13.92% | 7.01% | −0.68% |
Return on Invested Capital (Normalized) | 8.99% | 4.52% | −0.50% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Lczlhdcrsk | Zdgf | $204.5 Bil | |||
| Danaher Corp
DHR
| Fbcbrqzbj | Wtlzqbp | $177.8 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Rgfjshykw | Bvrkxvp | $39.4 Bil | |||
| IQVIA Holdings Inc
IQV
| Slmsxvs | Xxhmwh | $37.7 Bil | |||
| Agilent Technologies Inc
A
| Npxxvxbdb | Rmkk | $36.8 Bil | |||
| Mettler-Toledo International Inc
MTD
| Cttcrsfvf | Cmqtwjy | $28.9 Bil | |||
| Icon PLC
ICLR
| Hgzrqzw | Dqgmwcc | $26.3 Bil | |||
| Waters Corp
WAT
| Qfsjrhhf | Zssy | $17.1 Bil | |||
| Illumina Inc
ILMN
| Qzsjzdxhk | Hldbhy | $16.8 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/adf521c2-d9af-477d-a6bc-03ec7ca34c40.jpg)